Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples.
Ho-Pun-Cheung A, Bazin H, Boissière-Michot F, Mollevi C, Simony-Lafontaine J, Landas E, Bleuse JP, Chardès T, Prost JF, Pèlegrin A, Jacot W, Mathis G, Lopez-Crapez E. Ho-Pun-Cheung A, et al. Among authors: pelegrin a. Br J Cancer. 2020 Feb;122(3):397-404. doi: 10.1038/s41416-019-0670-8. Epub 2019 Dec 3. Br J Cancer. 2020. PMID: 31792349 Free PMC article.
Anti-HER2 vaccines: new prospects for breast cancer therapy.
Ladjemi MZ, Jacot W, Chardès T, Pèlegrin A, Navarro-Teulon I. Ladjemi MZ, et al. Among authors: pelegrin a. Cancer Immunol Immunother. 2010 Sep;59(9):1295-312. doi: 10.1007/s00262-010-0869-2. Epub 2010 Jun 8. Cancer Immunol Immunother. 2010. PMID: 20532501 Free PMC article. Review.
Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transfer.
Ho-Pun-Cheung A, Bazin H, Gaborit N, Larbouret C, Garnero P, Assenat E, Castan F, Bascoul-Mollevi C, Ramos J, Ychou M, Pèlegrin A, Mathis G, Lopez-Crapez E. Ho-Pun-Cheung A, et al. Among authors: pelegrin a. PLoS One. 2012;7(7):e37065. doi: 10.1371/journal.pone.0037065. Epub 2012 Jul 19. PLoS One. 2012. PMID: 22829865 Free PMC article.
Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.
Le Clorennec C, Bazin H, Dubreuil O, Larbouret C, Ogier C, Lazrek Y, Garambois V, Poul MA, Mondon P, Barret JM, Mathis G, Prost JF, Pèlegrin A, Chardès T. Le Clorennec C, et al. Among authors: pelegrin a. Mol Cancer Ther. 2017 Jul;16(7):1312-1323. doi: 10.1158/1535-7163.MCT-16-0886. Epub 2017 May 15. Mol Cancer Ther. 2017. PMID: 28507002 Free article.
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.
Gaborit N, Larbouret C, Vallaghe J, Peyrusson F, Bascoul-Mollevi C, Crapez E, Azria D, Chardès T, Poul MA, Mathis G, Bazin H, Pèlegrin A. Gaborit N, et al. Among authors: pelegrin a. J Biol Chem. 2011 Apr 1;286(13):11337-45. doi: 10.1074/jbc.M111.223503. Epub 2011 Jan 31. J Biol Chem. 2011. PMID: 21282108 Free PMC article.
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.
Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, Robert B, Bibeau F, Bleuse JP, Crapez E, Ychou M, Pèlegrin A. Assenat E, et al. Among authors: pelegrin a. Oncotarget. 2015 May 20;6(14):12796-808. doi: 10.18632/oncotarget.3473. Oncotarget. 2015. PMID: 25918250 Free PMC article. Clinical Trial.
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz LB, Roger P, Guiu S, Derocq D, Robin G, Michaud HA, Delpech H, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Simony-Lafontaine J, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget JP, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E. Ashraf Y, et al. Among authors: pelegrin a. J Immunother Cancer. 2019 Feb 4;7(1):29. doi: 10.1186/s40425-019-0498-z. J Immunother Cancer. 2019. PMID: 30717773 Free PMC article.
Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells.
Bourillon L, Demontoy S, Lenglet A, Zampieri A, Fraisse J, Jarlier M, Boissière-Michot F, Perrochia H, Rathat G, Garambois V, Bonnefoy N, Michaud HA, Chardès T, Tosi D, Pèlegrin A, Azria D, Larbouret C, Bourgier C. Bourillon L, et al. Among authors: pelegrin a. Int J Radiat Oncol Biol Phys. 2020 Apr 1;106(5):1039-1051. doi: 10.1016/j.ijrobp.2019.12.020. Epub 2020 Jan 17. Int J Radiat Oncol Biol Phys. 2020. PMID: 31959545
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models.
Thomas G, Chardès T, Gaborit N, Mollevi C, Leconet W, Robert B, Radosevic-Robin N, Penault-Llorca F, Gongora C, Colombo PE, Lazrek Y, Bras-Goncalves R, Savina A, Azria D, Bazin H, Pèlegrin A, Larbouret C. Thomas G, et al. Among authors: pelegrin a. Oncotarget. 2014 Aug 30;5(16):7138-48. doi: 10.18632/oncotarget.2231. Oncotarget. 2014. PMID: 25216528 Free PMC article.
Examination of HER3 targeting in cancer using monoclonal antibodies.
Gaborit N, Abdul-Hai A, Mancini M, Lindzen M, Lavi S, Leitner O, Mounier L, Chentouf M, Dunoyer S, Ghosh M, Larbouret C, Chardès T, Bazin H, Pèlegrin A, Sela M, Yarden Y. Gaborit N, et al. Among authors: pelegrin a. Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):839-44. doi: 10.1073/pnas.1423645112. Epub 2015 Jan 6. Proc Natl Acad Sci U S A. 2015. PMID: 25564668 Free PMC article.
166 results